Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Postoperative chemoradiotherapy is the recommended standard therapy for patients with locally advanced rectal cancer. In recent years, encouraging results with preoperative radiotherapy have been reported. We compared preoperative chemoradiotherapy with postoperative chemoradiotherapy for locally advanced rectal cancer. METHODS: We randomly assigned patients with clinical stage T3 or T4 or node-positive disease to receive either preoperative or postoperative chemoradiotherapy. The preoperative treatment consisted of 5040 cGy delivered in fractions of 180 cGy per day, five days per week, and fluorouracil, given in a 120-hour continuous intravenous infusion at a dose of 1000 mg per square meter of body-surface area per day during the first and fifth weeks of radiotherapy. Surgery was performed six weeks after the completion of chemoradiotherapy. One month after surgery, four five-day cycles of fluorouracil (500 mg per square meter per day) were given. Chemoradiotherapy was identical in the postoperative-treatment group, except for the delivery of a boost of 540 cGy. The primary end point was overall survival. RESULTS: Four hundred twenty-one patients were randomly assigned to receive preoperative chemoradiotherapy and 402 patients to receive postoperative chemoradiotherapy. The overall five-year survival rates were 76 percent and 74 percent, respectively (P=0.80). The five-year cumulative incidence of local relapse was 6 percent for patients assigned to preoperative chemoradiotherapy and 13 percent in the postoperative-treatment group (P=0.006). Grade 3 or 4 acute toxic effects occurred in 27 percent of the patients in the preoperative-treatment group, as compared with 40 percent of the patients in the postoperative-treatment group (P=0.001); the corresponding rates of long-term toxic effects were 14 percent and 24 percent, respectively (P=0.01). CONCLUSIONS: Preoperative chemoradiotherapy, as compared with postoperative chemoradiotherapy, improved local control and was associated with reduced toxicity but did not improve overall survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among the patients in whom abdominoperineal resection (APR) was considered necessary at the time of enrollment, the percentage of patients in whom sphincter preservation was possible was significantly higher in the preoperative chemoradiotherapy group [119].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“there was no significant difference in the 5-year survival rate”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“but the local recurrence rate and incidence of grade 3 or higher adverse events were significantly lower in the preoperative chemoradiotherapy group.”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
Kapiteijn, E., Marijnen, C. A. M., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T., Rutten, H. J. T., Pahlman, L., Glimelius, B., van Krieken, J. H. J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010580 · Cited by 4,205
Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer
(1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361402 · Cited by 2,517
Effective Surgical Adjuvant Therapy for High-Risk Rectal Carcinoma
Krook, J. E., Moertel, C. G., Gunderson, L. L., Wieand, H. S., Collins, R. T., Beart, R. W., Kubista, T. P., Poon, M. A., Meyers, W. C., Mailliard, J. A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241101 · Cited by 1,879
Statistical methods in cancer research. Vol. 1. The analysis of case-control studies
(1983) · Food and Chemical Toxicology · doi:10.1016/0278-6915(83)90281-8 · Cited by 1,716
Prolongation of the Disease-Free Interval in Surgically Treated Rectal Carcinoma
Gastrointestinal Tumor Study Group (1985) · New England Journal of Medicine · doi:10.1056/nejm198506063122301 · Cited by 1,130
(2001) · The Lancet · doi:10.1016/s0140-6736(01)06409-1 · Cited by 870
Preoperative Radiotherapy for Resectable Rectal Cancer: A Meta-analysis
Cammà, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxì, A., & Cottone, M. (2000) · JAMA · doi:10.1001/jama.284.8.1008 · Cited by 754
NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer
(1990) · JAMA · doi:10.1001/jama.264.11.1444 · Cited by 394
Hyams, D. M., Mamounas, E. P., Petrelli, N., Rockette, H., Jones, J., Wieand, S. H., Deutsch, M., Wickerham, L. D., Fisher, B., & Wolmark, N. (1997) · Diseases of the Colon & Rectum · doi:10.1007/bf02054976 · Cited by 360
Research works printed but not linked: 3
- Seegenschmiedt MH, 1993, Strahlenther Onkol, 169, 83
- Pichlmaier H, 1994, Chirurg, 65, 411
- Hermanek P. What can the pathologist tell the surgeon about rectal cancer resection? In: Scholefield JH, ed. Challenges in colorectal cancer. Oxford, England: Blackwell, 2000:81-90.
Cited by
Items 601–700 of 1,004
Rectal cancer staging post neoadjuvant therapy – how should the changes be assessed?
Bateman, A. C., Jaynes, E., & Bateman, A. R. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03292.x · Cited by 77
“operable versus inoperable at presentation, the expected level of CRM positivity may well be low (1–3%) as identified in recent studies and therefore non-contributory to differentiating between alternative neoadjuvant strategies.(1,16) Standardized analysis as to the degree of tumour regression in these trials may pro…”
BackgroundResultCeyhan, G. O., Liebl, F., Maak, M., Schuster, T., Becker, K., Langer, R., Demir, İ. E., Hartel, M., Frieß, H., & Rosenberg, R. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181fcab8d · Cited by 79
Xin Min, Z. H. O. U., Wang, B., Li, F., Wang, J., & Fu, W. (2017) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000819 · Cited by 77
Chioreso, C., Vecchio, N. J. D., Schweizer, M. L., Schlichting, J. A., Gribovskaja‐Rupp, I., & Charlton, M. E. (2018) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001198 · Cited by 78
Dittfeld, C., Dietrich, A., Peickert, S., Hering, S., Baumann, M. A., Grade, M., Ried, T., & Kunz‐Schughart, L. A. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.06.034 · Cited by 80
“While surgery constitutes the primary treatment, preoperative 5-FU (5-fluoruracil)-based chemoradiotherapy (CT/RT) is recommended for locally advanced rectal adenocarcinomas according to the CAO/ARO/AIO-94 trial of the German Rectal Cancer Study Group [47].”
Chen, H.-Y., Feng, L.-L., Li, M., Ju, H., Ding, Y., Lan, M., Song, S.-M., Han, W.-D., Yu, L., Wei, M., et al. (2021) · The Oncologist · doi:10.1002/onco.13707 · Cited by 82
“Several tumor regression grading (TRG) systems have been established to stratify tumor pathologic response to nCRT for LARC.”
BackgroundInfluentialTargeted Therapy for Colorectal Cancer
Sakata, S., & Larson, D. W. (2022) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2021.11.006 · Cited by 95
Kim, Y. S., Kim, J. H., Yoon, S. M., Choi, E. K., Ahn, S. D., Lee, S.-W., Kim, J. C., Yu, C. S., Kim, H. C., Kim, T. W., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.08.065 · Cited by 76
Moureau-Zabotto, L., Farnault, B., de Chaisemartin, C., Esterni, B., Lelong, B., Viret, F., Giovannini, M. F., Monges, G. M., Delpéro, J., Bories, E., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.02.025 · Cited by 85
Chang, G. J., Rodríguez-Bigas, M. A., Eng, C., & Skibber, J. M. (2009) · Cancer · doi:10.1002/cncr.24622 · Cited by 81
“European randomized trials have shown that patients receiving preoperative chemoradiation are as much as twice more likely to complete adjuvant chemotherapy after resection than are patients receiving postoperative chemoradiation.(7,14)”
BackgroundResultMucinous Rectal Cancer: Effectiveness of Preoperative Chemoradiotherapy and Prognosis
Shin, U. S., Yu, C. S., Kim, J. H., Kim, T. W., Lim, S.-B., Yoon, S. N., Yoon, Y. S., Kim, C. W., & Kim, J. C. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1612-8 · Cited by 76
“Preoperative chemoradiation is the current standard of care for patients with stage II and III rectal cancer.(3,13) The goals of preoperative chemoradiotherapy include improved local control, sphincter preservation, and prolongation of survival, as measured by tumor downstaging or pathologic complete response (pCR).”
Klautke, G., Feyerherd, P., Ludwig, K., Prall, F., Foitzik, T., & Fietkau, R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602492 · Cited by 76
“Moreover, randomised trials have shown that neoadjuvant chemoradiotherapy improves local control compared with postoperative chemoradiation in primary resectable tumours (Roh et al, 2001; Sauer et al, 2004).”
BackgroundResultSelf-citationCurrent Approaches and Challenges for Monitoring Treatment Response in Colon and Rectal Cancer
McKeown, E., Nelson, D. W., Johnson, E. K., Maykel, J. A., Stojadinovic, A., Nissan, A., Avital, I., Brücher, B. L. D. M., & Steele, S. R. (2014) · Journal of Cancer · doi:10.7150/jca.7987 · Cited by 77
Lee, S. Y., Kim, C. H., Kim, Y. J., & Kim, H. R. (2017) · Surgical Endoscopy · doi:10.1007/s00464-017-5718-3 · Cited by 76
Chorbińska, J., Krajewski, W. R., & Zdrojowy, R. (2021) · Translational Cancer Research · doi:10.21037/tcr-20-2589 · Cited by 80
“Late severe urological complications after irradiation of colorectal cancer occur in 2–4% of patients (59).”
BackgroundEffects of Obesity in Rectal Cancer Surgery
Chern, H., Chou, J. F., Donkor, C., Shia, J., Guillem, J. G., Nash, G. M., Paty, P. B., Temple, L. K. F., Wong, D. W., & Weiser, M. R. (2010) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2010.03.010 · Cited by 76
Yu, T.-K., Bhosale, P., Crane, C. H., Iyer, R. B., Skibber, J. M., Rodríguez-Bigas, M. A., Feig, B. W., Chang, G. J., Eng, C., Wolff, R. A., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.11.018 · Cited by 78
“Each in-field recurrence was further classified into one of four categories: (1) Low pelvis: Below the top of the acetabulum, (2) Mid pelvis: From the top of the acetabulum to the bottom of the sacroiliac joint, (3) High pelvis: Above the bottom of the sacroiliac joint, and (4) Presacral: Within 2 cm anterior to the s…”
MethodNg, S. S. M., Lee, J. F. Y., Yiu, R. Y. C., Li, J. C. M., Hon, S. S. F., Mak, T. W. C., Ngo, D. K. Y., Leung, W. W., & Leung, K. L. (2013) · Surgical Endoscopy · doi:10.1007/s00464-013-3187-x · Cited by 75
Restivo, A., Zorcolo, L., Cocco, I. M. F., Manunza, R., Margiani, C., Marongiu, L., & Casula, G. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2669-8 · Cited by 84
Yu, S., Tait, D., Chau, I., & Brown, G. M. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.06.2052 · Cited by 81
Perez, R. O., Pereira, D. D., Proscurshim, I., Gama-Rodrigues, J. J., Rawet, V., Julião, G. P. S., Kiss, D. R., Cecconello, I., & Habr‐Gama, A. (2009) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181a0af4b · Cited by 75
“The use of neoadjuvant chemoradiation therapy for invasive rectal cancer has led to a shift toward earlier disease staging as a result of tumor downstaging in these patients.(11,12,17) In fact, after neoadjuvant CRT for patients with Stages 2 and 3, up to 50% of patients may present pathologic Stages 0 and I after rad…”
MethodHuebner, M., Wolff, B. G., Smyrk, T. C., Aakre, J. A., & Larson, D. W. (2012) · World Journal of Surgery · doi:10.1007/s00268-011-1409-8 · Cited by 75
Preoperative Single Fraction Partial Breast Radiotherapy for Early-Stage Breast Cancer
Palta, M., Yoo, S., Adamson, J. D., Prosnitz, L. R., & Horton, J. K. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.09.041 · Cited by 79
“The use of preoperative RT in other disease sites has led to smaller treatment volumes and less normal tissue toxicity (8, 9).”
Chessin, D. B., Enker, W. E., Cohen, A. M., Paty, P. B., Weiser, M. R., Saltz, L. B., Minsky, B. D., Wong, W. D., & Guillem, J. G. (2005) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2005.02.027 · Cited by 75
Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer
Tang, M., Lu, X., Zhang, C., Du, C., Cao, L., Hou, T., Li, Z., Tu, B., Cao, Z., Li, Y., et al. (2017) · Theranostics · doi:10.7150/thno.18804 · Cited by 75
“5-Fluorouracil (5-FU) and radiation is a standard treatment regimen for colorectal cancers (4, 5).”
BackgroundGérard, J., Chamorey, E., Gourgou-Bourgade, S., Benezery, K., de Laroche, G., Mahé, M.-A., Boige, V., & Juzyna, B. (2015) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2015.04.003 · Cited by 87
“Many randomized trials have shown that neoadjuvant chemoradiotherapy (nCRT) or short course radiotherapy improves local control [2–6].”
BackgroundMargalit, D. N., Mamon, H. J., Ancukiewicz, M., Kobayashi, W. K., Ryan, D. P., Blaszkowsky, L. S., Clark, J. W., Willett, C. G., & Hong, T. S. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.12.056 · Cited by 79
miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy
Kheirelseid, E. A. H., Miller, N., Chang, K. H., Curran, C. E., Hennessey, E., Sheehan, M., Newell, J., Lemetre, C., Balls, G., & Kerin, M. J. (2012) · International Journal of Colorectal Disease · doi:10.1007/s00384-012-1549-9 · Cited by 81
Acute and long-term gastrointestinal consequences of chemotherapy
Fiore, F. D., & Cutsem, E. V. (2009) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2008.11.016 · Cited by 74
“These include cancer of the rectum, prostate, gynaecologic tract, and upper GI tract [2–7].”
BackgroundLong-term urinary adverse effects of pelvic radiotherapy
Elliott, S. P., & Malaeb, B. S. (2010) · World Journal of Urology · doi:10.1007/s00345-010-0603-x · Cited by 77
“The only trial that describes urinary AEs mentions ‘‘bladder problems’’ in 2–4% [44].”
Wieder, H. A., Rosenberg, R., Lordick, F., Geinitz, H., Beer, A. J., Becker, K., Woertler, K., Dobritz, M., Siewert, J. R., Rummeny, E. J., et al. (2007) · Radiology · doi:10.1148/radiol.2433060421 · Cited by 74
“The overall 5-year survival rate in our study was almost identical to that recently reported by Sauer et al (10), with use of a cumulative external radiation dose of 50 Gy.”
ResultTan, Y., & Wu, H. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2017.11.002 · Cited by 76
van der Sande, M. E., Hupkens, B. J. P., Berbée, M., van Kuijk, S. M. J., Maas, M., Melenhorst, J., Beets, G. L., & Breukink, S. O. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.11.017 · Cited by 80
Value of Intraoperative Radiotherapy in Locally Advanced Rectal Cancer
Ferenschild, F. T. J., Vermaas, M., Nuyttens, J. J. M. E., Graveland, W. J., Marinelli, A. W. K. S., van der Sijp, J. R., Wiggers, T., Verhoef, C. K., Eggermont, A. M. M., & de Wilt, J. H. W. (2006) · Diseases of the Colon & Rectum · doi:10.1007/s10350-006-0651-x · Cited by 74
“In future multimodality treatment protocols for locally advanced rectal cancer, the addition of chemotherapy to radiotherapy should be considered.(44)”
BackgroundKlautke, G., Küchenmeister, U., Foitzik, T., Ludwig, K., Prall, F., Klar, E., & Fietkau, R. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603053 · Cited by 74
“In addition, it can enable patients to undergo more conservative sphincter-sparing surgery and there is a lower rate of acute side effects (Sauer et al, 2004).”
BackgroundSelf-citationUrogenital function following robotic and laparoscopic rectal cancer surgery: meta-analysis
Fleming, C., Cullinane, C. M., Lynch, N., Killeen, S., Coffey, J. C., & Peirce, C. (2021) · British journal of surgery · doi:10.1093/bjs/znaa067 · Cited by 74
Díaz-González, J. A., Calvo, F. Á., Cortés, J., Garcia-Sabrido, J. L., Gómez-Espí, M., del Valle, E., Muñoz-Jiménez, F., & Álvarez, E. F. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.09.020 · Cited by 73
Dean, C. J., Sykes, J., Cooper, R., Hatfield, P., Carey, B., Swift, S. E., Bacon, S. E., Thwaites, D., Sebag‐Montefiore, D., & Morgan, A. M. (2011) · British Journal of Radiology · doi:10.1259/bjr/11855927 · Cited by 79
“The third study demonstrated both reduced local recurrence and reduced acute and late toxicity for pre-operative CRT compared with post-operative CRT [9].”
BackgroundRole of Adjuvant Chemoradiation Therapy in Adenocarcinomas of the Ampulla of Vater
Krishnan, S., Rana, V., Evans, D. B., Varadhachary, G. A., Das, P., Bhatia, S., Delclos, M. E., Janjan, N. A., Wolff, R. A., Crane, C. H., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.07.2327 · Cited by 73
Mace, A. G., Gantt, G., Skacel, M., Pai, R. K., Hammel, J. P., & Kalady, M. F. (2013) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e3182a4b236 · Cited by 78
A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer
Ngan, C. Y., Yamamoto, H., Seshimo, I., Ezumi, K., Terayama, M., Hemmi, H., Takemasa, I., Ikeda, M., Sekimoto, M., & Monden, M. (2007) · Journal of Surgical Oncology · doi:10.1002/jso.20638 · Cited by 73
“It was also recently demonstrated that preoperative chemoradiotherapy is especially useful to prevent local recurrence [33,34].”
BackgroundQuality of life after rectal resection and multimodality therapy
Hassan, I., & Cima, R. R. (2007) · Journal of Surgical Oncology · doi:10.1002/jso.20916 · Cited by 83
“The COA/ARO/AIO-94 study [45] was a randomized comparison between preoperative chemotherapy and pelvic radiotherapy versus postoperative chemotherapy and pelvic radiotherapy.”
Pach, R., Kulig, J., Richter, P., Gach, T., Szura, M., & Kowalska, T. (2011) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-011-0890-8 · Cited by 77
“The conventional treatment inmost countries for clinical stage T3 or node-positive rectal cancer is preoperative treatment, since a significantly lower local recurrence rate and morbidity were reported after preoperative than postoperative chemoradiation in theGermanChirurgischeArbeitsgemeinschaft für Onkologie/Arbeit…”
BackgroundYang, K.-L., Yang, S.-H., Liang, W.-Y., Kuo, Y., Lin, J.-K., Lin, T.-C., Chen, W.-S., Jiang, J., Wang, H.-S., Chang, S., et al. (2013) · Radiation Oncology · doi:10.1186/1748-717x-8-43 · Cited by 75
“; licensee BioMed Central Lt Commons Attribution License (http://creativec reproduction in any medium, provided the or tumor and increase the probability of sphincter-sparing surgery [2-6].”
BackgroundNovel radiomic signature as a prognostic biomarker for locally advanced rectal cancer
Meng, Y., Zhang, Y., Dong, D., Li, C., Liang, X., Zhang, C., Wan, L., Zhao, X., Xu, K., Zhou, C., et al. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25968 · Cited by 78
“Neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME) is currently considered the standard combined modality treatment for patients with locally advanced rectal cancer (LARC).(1) This therapeutic strategy improves local control of the disease, but does not notably increase overall survival (…”
BackgroundOutcomes following surgery without radiotherapy for rectal cancer
Mathis, K. L., Larson, D. W., Dozois, E. J., Cima, R. R., Huebner, M., Haddock, M. G., Wolff, B. G., Nelson, H., & Pembérton, J. H. (2011) · British journal of surgery · doi:10.1002/bjs.7739 · Cited by 76
Watch-and-Wait Approach to Rectal Cancer: The Role of Imaging
Jayaprakasam, V. S., Alvarez, J. A., Omer, D. M. R., Gollub, M. J., Smith, J. J., & Petkovska, I. (2023) · Radiology · doi:10.1148/radiol.221529 · Cited by 75
Kim, S. H., Lee, J. M., Gupta, S., Han, J. K., & Choi, B. I. (2013) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.24387 · Cited by 73
Heron, D. E., Andrade, R. S., Beriwal, S., & Smith, R. P. (2008) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318162f150 · Cited by 72
Prospective assessment of imaging after preoperative chemoradiotherapy for rectal cancer
Pomerri, F., Pucciarelli, S., Maretto, I., Zandonà, M., Bianco, P. D., Amadio, L., Rugge, M., Nitti, D., & Muzzio, P. C. (2010) · Surgery · doi:10.1016/j.surg.2010.03.025 · Cited by 73
Kennecke, H. F., Berry, S., Wong, R., Zhou, C., Tankel, K., Easaw, J. C., Rao, S. C., Post, J., & Hay, J. H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.016 · Cited by 76
Kim, H. J., Boland, P. J., Meredith, D. S., Lis, E., Zhang, Z., Shi, W., Yamada, Y. J., & Goodman, K. A. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.01.021 · Cited by 72
“Age at radiotherapy, y 60 254 (52) >60 238 (48) Sex Female 216 (44) Male 276 (56) AJCC stage I 10 (2) II 177 (36) III 193 (39) IV 17 (3) Recurrence 29 (6) NA 66 (13) Radiotherapy dose, cGy <5040 24 (5) 5040 450 (91) 5040 18 (4) Chemotherapy regimen None 7 (1) 5-FU based 362 (74) FOLFOX based 84 (17) Irinotecan based/o…”
BackgroundHyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity
Tao, R., Tsai, C. J., Jensen, G. L., Eng, C., Kopetz, S., Overman, M. J., Skibber, J. M., Rodríguez-Bigas, M. A., Chang, G. J., You, Y. N., et al. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.12.015 · Cited by 75
Nakanishi, R., Akiyoshi, T., Toda, S., Murakami, Y., Taguchi, S., Oba, K., Hanaoka, Y., Nagasaki, T., Yamaguchi, T., Konishi, T., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08974-w · Cited by 76
Resch, G., de Vries, A., Öfner, D., Eisterer, W., Rabl, H., Jagoditsch, M., Gnant, M., & Thaler, J. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.06.008 · Cited by 74
Navarro, M., Dotor, E., Rivera, F., Sánchez‐Rovira, P., Vega-Villegas, M. E., Cervantes, A. M. R., García, J. L., Gallén, M., & Aranda, E. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.04.007 · Cited by 72
Ding, P., Liska, D., Tang, P., Shia, J., Saltz, L. B., Goodman, K. A., Downey, R. J., Nash, G. M., Temple, L. K. F., Paty, P. B., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31825b3a2b · Cited by 75
Rectal cancer: An evidence-based update for primary care providers
Gaertner, W. B., Kwaan, M. R., Madoff, R. D., & Melton, G. B. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i25.7659 · Cited by 91
Watch-and-Wait as a Therapeutic Strategy in Rectal Cancer
Bernier, L., Balyasnikova, S., Tait, D., & Brown, G. (2018) · Current Colorectal Cancer Reports · doi:10.1007/s11888-018-0398-5 · Cited by 81
The Status of Radical Proctectomy and Sphincter-Sparing Surgery in the United States
Ricciardi, R., Virnig, B. A., Madoff, R. D., Rothenberger, D. A., & Baxter, N. N. (2007) · Diseases of the Colon & Rectum · doi:10.1007/s10350-007-0250-5 · Cited by 71
Kim, H. J., Choi, G., Park, J. S., Park, S. Y., Cho, S. H., Lee, S. J., Kang, B. W., & Kim, J. G. (2017) · Oncotarget · doi:10.18632/oncotarget.20121 · Cited by 73
“Preoperative CRT may lead tumor downstaging, and it could also sterilize lymph nodes located in mesorectum and lateral pelvic side-wall [2, 12].”
BackgroundKSAR Study Group for Rectal Cancer (2017) · Korean Journal of Radiology · doi:10.3348/kjr.2017.18.1.132 · Cited by 70
“This is because the paradigm for supplementary treatment to surgery for rectal cancer has shifted from adjuvant to neoadjuvant therapy (1, 2).”
BackgroundInfluentialKim, S. H., Lee, J. M., Park, H. S., Eun, H. W., Han, J. K., & Choi, B. I. (2009) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21742 · Cited by 71
A Twenty-Year Experience with Adenocarcinoma of the Anal Canal
Chang, G. J., Gonzalez, R. J., Skibber, J. M., Eng, C., Das, P., & Rodrı́guez-Bigas, M. A. (2009) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181a79589 · Cited by 70
“These findings are similar to the current neoadjuvant approach to rectal carcinoma whereby neoadjuvant therapy results in improved disease-free survival and local control, but less difference in the development of distant metastases.(10) Ongoing Phase II and III studies in rectal carcinoma hope to address the optimal…”
ResultPucciarelli, S., Rampazzo, E., Briarava, M., Maretto, I., Agostini, M., Digito, M., Keppel, S., Friso, M. L., Lonardi, S., Paoli, A. D., et al. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2272-z · Cited by 73
Yasuda, K., Nirei, T., Tsuno, N. H., Nagawa, H., & Kitayama, J. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01940.x · Cited by 71
Local iontophoretic administration of cytotoxic therapies to solid tumors
Byrne, J. D., Jajja, M. N. R., O’Neill, A. T., Bickford, L. R., Keeler, A. W., Hyder, N., Wagner, K., Deal, A. M., Little, R., Moffitt, R. A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3009951 · Cited by 70
Uterine transposition: technique and a case report
Ribeiro, R., Rebolho, J. C., Tsumanuma, F. K., Brandalize, G. G., Trippia, C. H., & Saab, K. A. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.06.016 · Cited by 70
Treatment of colorectal cancer in older patients
Audisio, R. A., & Papamichael, D. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.196 · Cited by 76
Li, Z., Wang, X., Li, M., Liu, X.-J., Ye, Z., Song, B., Yuan, F., Yuan, Y., Xia, C., Zhang, X., et al. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i19.2388 · Cited by 73
Urinary adverse effects of pelvic radiotherapy.
Liberman, D., Mehus, B., & Elliott, S. P. (2014) · PubMed Central · doi:10.3978/j.issn.2223-4683.2014.04.01 · Cited by 74
“Brændengen M, Tveit KM, Bruheim K, et al. Late patientreported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study.”
BackgroundMethodInfluentialCukier, M., Smith, A. J., Milot, L. M., Chu, W., Chung, H. T.-K., Fenech, D. S., Herschorn, S., Ko, Y. J., Rowsell, C. H., Soliman, H., et al. (2012) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2012.05.001 · Cited by 69
Phase II Study of Preoperative Helical Tomotherapy for Rectal Cancer
Ridder, M. D., Tournel, K., Nieuwenhove, Y. V., Engels, B., Hoorens, A., Everaert, H., de Beeck, B. O., Vinh‐Hung, V., Grève, J. D., Delvaux, G., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.07.2332 · Cited by 70
Radiation therapy in the elderly: More side effects and complications?
Gómez‐Millán, J. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.11.004 · Cited by 76
Valentini, V., Glimelius, B. L. G., Haustermans, K. M., Marijnen, C. A. M., Rödel, C. M., Gambacorta, M. A., Boelens, P. G., Aristei, C., & van de Velde, C. J. �. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.10.024 · Cited by 75
“At 11 years follow-up the preoperative LCRTCT approach was associated with higher LC, less toxicity and increased sphincter preservation in a subgroup [9,16].”
BackgroundSelf-citationEffect of Neoadjuvant Therapy on Local Recurrence after Resection of Pancreatic Adenocarcinoma
Greer, S. E., Pipas, M., Sutton, J. E., Zaki, B. I., Tsapakos, M. J., Colacchio, T. A., Gibson, J. J., Wiener, D. C., Ripple, G. H., & Barth, R. J. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.10.002 · Cited by 69
The English National Low Rectal Cancer Development Programme: key messages and future perspectives
Moran, B. J., Holm, T., Branagan, G., Chave, H., Quirke, P., West, N. P., Brown, G. M., Glynne‐Jones, R., Sebag‐Montefiore, D., Cunningham, C., et al. (2013) · Colorectal Disease · doi:10.1111/codi.12501 · Cited by 70
Cutsem, E. V., Dicato, M. A., Haustermans, K. M., Arber, N., Bosset, J.-F., Cunningham, D., de Gramont, A., Díaz‐Rubio, E., Ducreux, M. P., Goldberg, R. M., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn358 · Cited by 78
Treatment of Locally Recurrent Rectal Carcinoma in Previously (Chemo)Irradiated Patients: A Review
van der Meij, W., Rombouts, A. J. M., Rütten, H., Bremers, A. J. A., & de Wilt, J. H. W. (2016) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000547 · Cited by 74
Macchia, G., Gambacorta, M. A., Masciocchi, C., Chiloiro, G., Mantello, G., di Benedetto, M., Lupattelli, M., Palazzari, E., Belgioia, L., Bacigalupo, A., et al. (2017) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2017.04.004 · Cited by 78
“CRT is associated with improved local control (LC) rate, tolerable toxicity profile and high compliance rate, and tumor downsizing with a potentially increased sphincter preservation rate in patients with low-lying tumors [1,2].”
BackgroundMR-guided radiotherapy in rectal cancer: First clinical experience of an innovative technology
Chiloiro, G., Boldrini, L., Meldolesi, E., Re, A., Cellini, F., Cusumano, D., Corvari, B., Mantini, G., Balducci, M., Valentini, V., et al. (2019) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2019.04.006 · Cited by 70
“In preoperative standard treatment studies with concomitant 5-FU chemotherapy the rate of proctitis and G3 diarrhea was variable from 15 to 40% [2,42,43].”
BackgroundGenovesi, D., Filippone, A., Cèfaro, G. A., Trignani, M., Vinciguerra, A., Augurio, A., Tommaso, M. D., Borzillo, V., Sabatino, F. D., Innocenti, P., et al. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.07.090 · Cited by 68
Mason, M. C., Massarweh, N. N., Tzeng, C.-W. D., Chiang, Y., Chun, Y. S., Aloia, T. A., Javle, M. M., Vauthey, J., & Cao, H. S. T. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09536-w · Cited by 74
Rawson, R. V., Adhikari, C., Bierman, C., Lo, S., Shklovskaya, E., Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Shannon, K. F., Gonzalez, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.03.006 · Cited by 72
Banerjee, R. N., Chakraborty, S., Nygren, I., & Sinha, R. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.09.036 · Cited by 69
“Prospective randomized trials have shown that up to 10% of such patients are unable to complete treatment because of bowel toxicity (1).”
Smith, F. M., Gallagher, W. M., Fox, E., Stephens, R. B., Rexhepaj, E., Petricoin, E. F., Liotta, L. A., Kennedy, M., & Reynolds, J. V. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000245577.68151.bd · Cited by 68
Ishii, Y., Hasegawa, H., Endo, T., Okabayashi, K., Ochiai, H., Moritani, K., Watanabe, M., & Kitagawa, Y. (2010) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2010.05.017 · Cited by 71
Intersphincteric resection for very low rectal cancer: a systematic review
Akagi, Y., Kinugasa, T., & Shirouzu, K. (2012) · Surgery Today · doi:10.1007/s00595-012-0394-3 · Cited by 71
Oberholzer, K., Menig, M., Kreft, A., Schneider, A., Junginger, T., Heintz, A., Kreitner, K., Hötker, A. M., Hansen, T., Düber, C., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.08.057 · Cited by 76
Self-citationCecchin, E., Agostini, M., Pucciarelli, S., Paoli, A. D., Canzonieri, V., Sigon, R., Mattia, E. D., Friso, M. L., Biason, P., Visentin, M. C., et al. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.25 · Cited by 70
Rectal cancer surgery: A brief history
Galler, A. S., Petrelli, N. J., & Shakamuri, S. P. (2010) · Surgical Oncology · doi:10.1016/j.suronc.2010.01.001 · Cited by 70
“The pre-operative group displayed improved local control with less toxicity without any survival difference [26].”
BackgroundSurvival after pelvic exenteration for T4 rectal cancer
Kusters, M., Austin, K. K. S., Solomon, M. J., Lee, P. J., Nieuwenhuijzen, G. A. P., & Rutten, H. J. T. (2014) · British journal of surgery · doi:10.1002/bjs.9683 · Cited by 68
Engels, B., Ridder, M. D., Tournel, K., Sermeus, A. B. L., Coninck, P. D., Verellen, D., & Storme, G. A. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.017 · Cited by 72
Zhu, J. Y., Liu, F., Gu, W., Lian, P., Sheng, W., Xu, J., Cai, G., Shi, D., Cai, S., & Zhang, Z. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-70 · Cited by 70
“Some significant benefits of neoadjuvant CRT, such as better local control and sphincter preservation, have been shown in patients with stage II/III rectal cancer [1-3].”
BackgroundAdvanced gastric cancer: What we know and what we still have to learn
Coccolini, F., Montori, G., Ceresoli, M., Cima, S., Valli, M. C., Nita, G. E., Heyer, A., Catena, F., & Ansaloni, L. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i3.1139 · Cited by 76
Fietkau, R., Rödel, C. M., Hohenberger, W., Raab, R., Hess, C. F., Liersch, T., Becker, H., Wittekind, C., Hutter, M., Hager, E., et al. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.10.020 · Cited by 68
“Our study group demonstrated in the German Rectal Cancer Trial (CAO/ARO/AIO-94) that neoadjuvant chemoradiotherapy (CRT) is superior to adjuvant treatment in terms of the locoregional recurrence rate (LRR) and toxicity ( 1 ).”
MethodResultSelf-citationAbbott, D. E., Tzeng, C.-W. D., Merkow, R. P., Cantor, S. B., Chang, G. J., Katz, M. H. G., Bentrem, D. J., Bilimoria, K. Y., Crane, C. H., Varadhachary, G. R., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-2882-0 · Cited by 67
“This approach has gained acceptance in rectal and esophageal cancer in improving locoregional control and survival, respectively, in large part because of significantly higher rates of completing multimodality therapy, and improvement in patient selection.(15,16) However, in pancreatic cancer, while the neoadjuvant ch…”
Two countries – Two treatment strategies for rectal cancer
Glimelius, B. L. G., Myklebust, T. Å., Lundqvist, K., Wibe, A., & Guren, M. G. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.11.010 · Cited by 68
Schrag, D., Weiser, M. R., Saltz, L. B., Mamon, H. J., Gollub, M. J., Basch, E., Venook, A. P., & Shi, Q. (2019) · Clinical Trials · doi:10.1177/1740774518824539 · Cited by 70
Diers, J., Wagner, J., Baum, P., Lichthardt, S., Kastner, C., Matthes, N., Matthes, H., Germer, C.-T., Löb, S., & Wiegering, A. (2020) · BJS Open · doi:10.1002/bjs5.50254 · Cited by 67
Metadata
- Authors
- Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., Karstens, J.-H., Liersch, T., Schmidberger, H., & Raab, R.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Leipzig University (DE)
- University of Rostock (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Hospital of the Brothers of St. John of God (AT)
- Klinikum Klagenfurt (AT)
- University of Göttingen (DE)
- Medizinische Hochschule Hannover (DE)
- Klinikum Oldenburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-10-21
- Volume
- 351
- Issue
- 17
- Pages
- 1731-1740
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125452425
- Cited by
- 6,050
- References
- 19
- Citations by year
- 2026: 178 · 2025: 205 · 2024: 232 · 2023: 275 · 2022: 310 · 2021: 324 · 2020: 322 · 2019: 321 · 2018: 305 · 2017: 298 · 2016: 291 · 2015: 348 · 2014: 340 · 2013: 333 · 2012: 346
- FWCI
- 82.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Colorectal and Anal Carcinomas
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- rectal cancer, locally advanced rectal cancer, neoadjuvant chemoradiotherapy, postoperative chemoradiotherapy, neoadjuvant therapy, adjuvant therapy, 5-fluorouracil, boost radiotherapy, local recurrence, overall survival, treatment toxicity
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Combined Modality Therapy, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Postoperative Care, Postoperative Complications, Preoperative Care, Quality Control, Radiotherapy, Rectal Neoplasms, Incidence, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.